Norlase’s award-winning pattern LIO Lynx

Danish ophthalmic laser technology company Norlase’s latest innovation, Lynx, a pattern laser indirect ophthalmoscope (LIO), has received the US Food and Drug Administration (FDA) premarket notification 510(k) clearance and the CE mark.

“The world’s first and only pattern scanning LIO, Lynx is battery-powered and provides surgeons an untethered laser solution that empowers them to treat virtually anywhere,” said Oliver Hvidt, CEO and co-founder of Norlase.

“The most important resource for today’s ophthalmologists is time. That’s why they’ve been asking for pattern LIO ever since the invention of pattern lasers more than 15 years ago. Faster LIO treatment means less ergonomic stress, more quality time with patients and more practice days that end on time,” he said.

New Zealand distributor Titan Optical’s Cam Gordon said Lynx is a great example of Norlase’s ability to think outside the box. “It’s an engineering marvel in many ways, no one has ever managed to make a pattern LIO before.”

Lynx’s laser, scanner and delivery system are fully integrated into the ultralight headset. Its full pattern palette includes 2x2 to 5x5 grids, triple arcs and circles, simplyClear safety filters and multilingual voice control of patterns and parameters.

Norlase won a prestigious 2025 Prism Award for Lynx in the biomedical category. Following the success of its Lion battery-powered LIO and green laser, this is Norlase’s second Prism Award, reinforcing the company’s reputation for pioneering advancements in retinal laser treatment, said Hvidt.